Equities analysts predict that Icon Plc (NASDAQ:ICLR) will report earnings of $1.41 per share for the current fiscal quarter, according to Zacks Investment Research. Eight analysts have made estimates for Icon’s earnings, with estimates ranging from $1.38 to $1.43. Icon reported earnings per share of $1.26 during the same quarter last year, which would suggest a positive year-over-year growth rate of 11.9%. The company is scheduled to issue its next earnings report on Thursday, February 15th.
According to Zacks, analysts expect that Icon will report full year earnings of $5.37 per share for the current fiscal year, with EPS estimates ranging from $5.34 to $5.38. For the next fiscal year, analysts forecast that the business will post earnings of $6.00 per share, with EPS estimates ranging from $5.89 to $6.07. Zacks’ EPS calculations are an average based on a survey of sell-side analysts that follow Icon.
Icon (NASDAQ:ICLR) last posted its quarterly earnings results on Thursday, October 26th. The medical research company reported $1.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.32 by $0.03. Icon had a return on equity of 28.42% and a net margin of 16.37%. The business had revenue of $440.30 million for the quarter, compared to analyst estimates of $438.09 million. During the same period last year, the company earned $1.19 EPS. Icon’s revenue for the quarter was up 4.8% compared to the same quarter last year.
Icon (ICLR) opened at $113.97 on Friday. The company has a current ratio of 1.90, a quick ratio of 1.90 and a debt-to-equity ratio of 0.31. Icon has a 1 year low of $76.46 and a 1 year high of $124.48. The stock has a market capitalization of $6,160.00, a P/E ratio of 22.13, a P/E/G ratio of 1.60 and a beta of 0.61.
Several institutional investors and hedge funds have recently added to or reduced their stakes in ICLR. Koch Industries Inc. lifted its stake in shares of Icon by 17,508.8% in the 2nd quarter. Koch Industries Inc. now owns 666,140 shares of the medical research company’s stock valued at $659,000 after purchasing an additional 662,357 shares during the period. FMR LLC lifted its stake in shares of Icon by 38.4% in the 2nd quarter. FMR LLC now owns 2,291,005 shares of the medical research company’s stock valued at $224,037,000 after purchasing an additional 635,950 shares during the period. Janus Henderson Group PLC lifted its stake in shares of Icon by 48.4% in the 2nd quarter. Janus Henderson Group PLC now owns 1,068,159 shares of the medical research company’s stock valued at $104,488,000 after purchasing an additional 348,292 shares during the period. Mckinley Capital Management LLC Delaware lifted its stake in shares of Icon by 2,674.8% in the 2nd quarter. Mckinley Capital Management LLC Delaware now owns 338,520 shares of the medical research company’s stock valued at $33,104,000 after purchasing an additional 326,320 shares during the period. Finally, Principal Financial Group Inc. lifted its stake in shares of Icon by 71.5% in the 3rd quarter. Principal Financial Group Inc. now owns 768,471 shares of the medical research company’s stock valued at $87,513,000 after purchasing an additional 320,356 shares during the period. Institutional investors own 89.66% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/01/20/brokerages-expect-icon-plc-iclr-will-post-earnings-of-1-41-per-share.html.
Icon Company Profile
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.